Lactobacillus Reuteri in Management of Helicobacter Pylori Infection in Dyspeptic Patients

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Addition of L. reuteri to the standard triple therapy improves H. Pylori treatment outcomes.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zagazig University
• Collaborator: BioGaia AB
• Treatments: Amoxicillin; Clarithromycin; Omeprazole

Criteria

Inclusion Criteria:

Inclusion of patients with these criteria

1. Age: 18-60 years

2. Any sex

3. Confirmed H. Pylori infection defined by pathological lesions and either histopathological confirmation of the organism, rapid urease test or H. Pylori antigen in stool

4. Good mentality to understand aim, benefits and steps of the study

5. Assumed availability during the study period

6. Written informed consent

Exclusion Criteria:

• Exclusion of

1. Patients with chronic diseases e.g. diabetes, renal failure, cirrhosis…etc.

2. Patients with malignancy.

3. Patients with gall bladder disorders.

4. Patients with peptic ulcer.

5. Patients with prior upper GIT surgery.

6. Patients with probiotics therapy in the last one month.

7. Patients with triple therapy, antibiotics, proton pump inhibitors and H2 receptor blockers therapy within one month.

8. Patients with known allergy to the used medications

-